Amicus Therapeutics, Inc. $FOLD Stock Holdings Boosted by Algert Global LLC

Key Points

• Algert Global LLC increased its stake in Amicus Therapeutics by 92.9%, now owning approximately 820,026 shares worth $6.69 million as reported in their recent SEC filing.
• Various institutional investors, including Aberdeen Group and Sei Investments, also boosted their holdings, reflecting growing confidence in the company's prospects.
• Research analysts have mixed views on the stock, with UBS raising its price target to $22 and Goldman Sachs lowering it to $9, while overall, Amicus received a consensus rating of "Moderate Buy."

Algert Global LLC raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 92.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 820,026 shares of the biopharmaceutical company's stock after purchasing an additional 394,943 shares during the period. Algert Global LLC owned about 0.27% of Amicus Therapeutics worth $6,691,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nuveen Asset Management LLC increased its stake in shares of Amicus Therapeutics by 4.4% during the 4th quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company's stock valued at $35,866,000 after acquiring an additional 159,139 shares during the last quarter. Nuveen LLC purchased a new position in Amicus Therapeutics in the first quarter valued at approximately $28,741,000. Northern Trust Corp lifted its position in Amicus Therapeutics by 5.9% during the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock valued at $31,761,000 after buying an additional 187,652 shares in the last quarter. Vestal Point Capital LP purchased a new position in shares of Amicus Therapeutics in the 4th quarter valued at $31,557,000. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Amicus Therapeutics by 0.3% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,276,371 shares of the biopharmaceutical company's stock valued at $26,735,000 after acquiring an additional 8,996 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on FOLD shares. The Goldman Sachs Group reduced their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Wall Street Zen raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Morgan Stanley upgraded Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. Finally, UBS Group raised their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Eight equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Stock Performance

NASDAQ FOLD traded up $0.20 during trading hours on Thursday, hitting $7.60. The company had a trading volume of 3,423,589 shares, compared to its average volume of 3,880,773. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. The firm has a market cap of $2.34 billion, a P/E ratio of -63.33 and a beta of 0.53. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The business has a fifty day simple moving average of $6.29 and a 200-day simple moving average of $7.23.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.